XML 52 R35.htm IDEA: XBRL DOCUMENT
v3.24.1

Stock-Based Compensation (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Schedule of Stock Options Issued and Outstanding Activities | Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Stock Options Issued and Outstanding Activities
|  | Number of Stock Options |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Term (Years) |  |  | Intrinsic Value(2) |
Outstanding stock options at December 31, 2021 |  |  | 1,419,242 |  |  | $ | 0.73 |  |  |  | 7.0 |  |  |  |  |
Granted(1) |  |  | 2,365,000 |  |  | $ | 3.68 |  |  |  |  |  |  |  |  |
Exercised |  |  | (965,342 | ) |  | $ | 0.72 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (253,523 | ) |  | $ | 3.83 |  |  |  |  |  |  |  |  |
Outstanding stock options at December 31, 2022 |  |  | 2,565,377 |  |  | $ | 3.14 |  |  |  | 8.3 |  |  | $ | 428 |
Granted(1) |  |  | 3,618,000 |  |  | $ | 1.32 |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  | $ | — |  |  |  |  |  |  |  |  |
Forfeited |  |  | (678,994 | ) |  | $ | 2.75 |  |  |  |  |  |  |  |  |
Outstanding stock options at December 31, 2023(3) |  |  | 5,504,383 |  |  | $ | 2.00 |  |  |  | 8.5 |  |  | $ | 765 |
Vested and exercisable stock options at December 31, 2023 |  |  | 2,339,527 |  |  | $ | 2.30 |  |  |  | 7.8 |  |  | $ | 529 |
(1) | Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
(2) | The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of December 31, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
(3) | The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of December 31, 2023 and December 31, 2022.
Schedule of Restricted Stock Award Activity | Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity
|  | Number of Restricted Stock Awards |  |  | Weighted Average Grant Date Fair Value |
Unvested restricted stock awards as of December 31, 2021 |  |  | 1,940,740 |  |  | $ | 12.76 |
Granted |  |  | 320,000 |  |  |  | 4.53 |
Vested |  |  | (169,320 | ) |  |  | 13.48 |
Forfeited |  |  | — |  |  |  | — |
Unvested restricted stock awards as of December 31, 2022(1) |  |  | 2,091,420 |  |  | $ | 11.44 |
Granted |  |  | 550,000 |  |  |  | 1.29 |
Vested |  |  | (303,980 | ) |  |  | 11.95 |
Forfeited |  |  | — |  |  |  | — |
Unvested restricted stock awards as of December 31, 2023 |  |  | 2,337,440 |  |  | $ | 8.99 |
(1) | The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics 2018 Equity Plan as of December 31, 2022. These 50,000 restricted stock awards were fully vested during the year ended December 31, 2023.
Schedule of Stock-Based Compensation Expense | The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense
|  | 2023 |  |  | 2022 |
|  | Years Ended December 31, |
|  | 2023 |  |  | 2022 |
Lucid Diagnostics 2018 Equity Plan – cost of revenue |  | $ | 63 |  |  | $ | 13 |
Lucid Diagnostics 2018 Equity Plan – sales and marketing |  |  | 948 |  |  |  | 968 |
Lucid Diagnostics 2018 Equity Plan - general and administrative |  |  | 4,455 |  |  |  | 12,691 |
Lucid Diagnostics 2018 Equity Plan - research and development |  |  | 296 |  |  |  | 187 |
PAVmed 2014 Equity Plan - cost of revenue |  |  | 37 |  |  |  | 3 |
PAVmed 2014 Equity Plan - sales and marketing |  |  | 463 |  |  |  | 654 |
PAVmed 2014 Equity Plan - general and administrative |  |  | 173 |  |  |  | 262 |
PAVmed 2014 Equity Plan - research and development |  |  | 387 |  |  |  | 213 |
Total stock-based compensation expense |  | $ | 6,822 |  |  | $ | 14,991 |
Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period | As of December 31, 2023, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period
|  | Unrecognized Expense |  |  | Weighted Average Remaining Service Period (Years) |
Lucid Diagnostics 2018 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 3,566 |  |  |  | 2.0 |
Restricted Stock Awards |  | $ | 1,167 |  |  |  | 2.2 |
PAVmed 2014 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 432 |  |  |  | 2.1 |
Schedule of Stock-based Compensation Valuation Assumptions | Schedule of Stock-based Compensation Valuation Assumptions
|  | 2023 |  |  | 2022 |
|  | Years Ended December 31, |
|  | 2023 |  |  | 2022 |
Expected term of stock options (in years) |  |  | 5.6 |  |  |  | 5.6 |
Expected stock price volatility |  |  | 74 | % |  |  | 71 | %
Risk free interest rate |  |  | 3.9 | % |  |  | 2.1 | %
Expected dividend yield |  |  | — | % |  |  | — | %

X
- Definition Schedule of unrecognized compensation expense and weighted average remaining service period [Table Text Block]. + References No definition available. + Details
Name: | LUCD_ScheduleOfUnrecognizedCompensationExpenseAndWeightedAverageRemainingServicePeriodTableTextBlock
Namespace Prefix: | LUCD_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References No definition available. + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration